Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03495479
Other study ID # OMN54-PC-02
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date January 2025
Est. completion date January 2029

Study information

Verified date October 2021
Source Omnitura Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Assessment of the effects of OMN54 (Aneustat) in a population of men with indolent prostate cancer who are otherwise healthy and free of significant co-morbidities and have chosen active surveillance for disease management. The investigators will assess how OMN54 affects PSA, overall tumor burden in addition to any changes in urinary flow. Other biomarkers will be tested to follow disease evolution.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2029
Est. primary completion date January 2028
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 72 Years
Eligibility Inclusion Criteria: - Localized prostate cancer suitable for active surveillance 1. Histologically confirmed adenocarcinoma of the prostate, with Gleason Score 6 or less prostate cancer. No limit in the percentage of cancer in each core or percentage of positive cores. 2. Male, 18 years or older 3. Able to swallow the soft gelatin capsule form of the drug which is ~6mm long. 4. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0. 5. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy). 6. ECOG Performance Status 0 or 1. 7. Patient has elected Active Surveillance as preferred management plan for prostate cancer. 8. Written informed consent obtained prior to any patient participation. 9. Participant is accessible and compliant for follow-up. 10. Prostate biopsy requirements: 1. If diagnosis was within one year of baseline visit, participant must have at least one biopsy with at least 10 cores. 2. If diagnosis was more than 1 year prior to baseline visit, participant must have a minimum of 2 biopsies, one of which must be within 2 years prior to baseline visit. 11. Voiding requirements: IPSS score of at least 15 and Qmax < 15 cc/s. 12. Adequate hematopoietic function as demonstrated by: - hemoglobin of = 9.0 g/dL without need for sustained blood transfusions - Platelet count =100,000 platelet/mm3 (100 x 109/L) - White Blood Cell (WBC) count = 2.0 x109/L and Absolute Neutrophil Count (ANC) =1.5 x109/L 13. Adequate hepatobiliary function as demonstrated by: - Total bilirubin level within normal limits - Alanine aminotransferase (ALT) levels within normal limits - Adequate renal function as demonstrated by creatinine level within normal limits or creatinine clearance within normal limits - Coagulation profile (PT, PTT, INR and TCT) within normal limits 14. If of reproductive capacity, willing to use an effective double barrier method of birth control (i.e., latex condom, partner use of diaphragm, cervical cap, etc) during the study and for 30 days after the last administration of OMN54 Exclusion Criteria: 1. Unwillingness or inability to undergo serial prostate biopsy or MRI. 2. History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > 5 years. 3. Previous surgical intervention for BPH 4. Active uncontrolled infection, including known history of HIV, hepatitis B or C 5. Concurrent uncontrolled hypertension 6. Congestive Heart Failure 7. Hepatic disease (cirrhosis, hepatitis, hepatocellular carcinoma or liver failure of unknown etiology) 8. Renal disease (glomerulonephritis, nephropathy, polycystic kidney disease) 9. Patients requiring new treatment of BPH (either medical or surgical) are not eligible. 10. Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption. 11. Known hypersensitivity to any of the three botanical constituents of Aneustatâ„¢ (OMN54); soy; any of the plants belonging to the Ganodermataceae family, e.g., reishi mushroom (Ganoderma lucidum, lingzhi); any plants belonging to Labiatae or Lamiaceae families, e.g., culinary herbs including basil, mint, rosemary, sage, savory, marjoram, oregano, thyme, lavender, and perilla; or Aneustatâ„¢ (OMN54) excipients. 12. Concurrent administration, or exposure within 30 days, of: - Investigational drugs and devices - Chemotherapy - Radiation therapy - Immunotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
OMN54
Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Omnitura Therapeutics, Inc. Vancouver Prostate Centre

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Prostate Specific Antigen Quarterly assessment of serum Prostate Specific Antigen (PSA) 12 months
Primary Changes in Tumor Size Changes in tumor size based on semi-annual MRI 12 months
Primary Changes in Urinary Flow Quartelry assessment of patient urinary flow based on patient IPSS Questionnaire 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A